The DOI matches its Crossref record; 512 of the 512 references it cites were found in a registry or an index.
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Open accessAbstract
Acetylcholinesterase (AChE) plays an important role in the pathogenesis of neurodegenerative diseases by influencing the inflammatory response, apoptosis, oxidative stress and aggregation of pathological proteins. There is a search for new compounds that can prevent the occurrence of neurodegenerative diseases and slow down their course. The aim of this review is to present the role of AChE in the pathomechanism of neurodegenerative diseases. In addition, this review aims to reveal the benefits of using AChE inhibitors to treat these diseases. The selected new AChE inhibitors were also assessed in terms of their potential use in the described disease entities. Designing and searching for new drugs targeting AChE may in the future allow the discovery of therapies that will be effective in the treatment of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
Items 201–400 of 512
Chen, C., Wei, Y.-Z., He, X., Li, D., Wang, G., Li, J.-J., & Zhang, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00936 · Cited by 91
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 91
Antinociceptive Effect of Amygdalin Isolated from Prunus armeniaca on Formalin-Induced Pain in Rats
Hwang, H.-J., Kim, P., Kim, C., Lee, H., Shim, I., Yin, C. S., Yang, Y. D., & Hahm, D. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1559 · Cited by 89
Proteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 89
Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats
Kulkarni, K., Kasture, S., & Mengi, S. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.66841 · Cited by 88
Poetini, M. R., Araújo, S. M., de Paula, M. T., Bortolotto, V. C., Meichtry, L. B., de Almeida, F. P., Jessé, C. R., Kunz, S. N., & Prigol, M. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.11.018 · Cited by 86
Dinel, A., Lucas, C., Guillemet, D., Layé, S., Pallet, V., & Joffre, C. (2020) · Nutrients · doi:10.3390/nu12061777 · Cited by 86
Hanieh, H., & Alzahrani, A. M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343486 · Cited by 85
Effect of ApoE Genotype on Response to Donepezil in Patients with Alzheimer’s Disease
Choi, S. H., Kim, S., Na, H. R., Kim, B., Yang, D. W., Kwon, J. C., & Park, M. Y. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000124752 · Cited by 85
Khajevand-Khazaei, M.-R., Ziaee, P., Motevalizadeh, S.-A., Rohani, M., Afshin‐Majd, S., Baluchnejadmojarad, T., & Roghani, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.001 · Cited by 85
Rogers, J. T., Mikkilineni, S., Cantuti‐Castelvetri, I., Smith, D. H., Huang, X., Bandyopadhyay, S., Cahill, C. M., Maccecchini, M. L., Lahiri, D. K., & Greig, N. H. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0513-5 · Cited by 84
Suzuki, M., Desmond, T. J., Albin, R. L., & Frey, K. A. (2001) · Synapse · doi:10.1002/syn.1089 · Cited by 84
Acetylcholinesterase and apoptosis
Jiang, H., & Zhang, X. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06236.x · Cited by 83
Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms
Giralt, A., Saavedra, A., Alberch, J., & Pérez‐Navarro, E. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-120023 · Cited by 83
Morphogenic role for acetylcholinesterase in axonal outgrowth during neural development.
Bigbee, J. W., Sharma, K. V., Gupta, J. J., & Dupree, J. L. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s181 · Cited by 81
Çiftçi, O., Özcan, C., Kamışlı, Ö., Çetin, A., Başak, N., & Aytaç, B. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1571-8 · Cited by 81
Maurice, T., Meunier, J., Feng, B., Ieni, J. R., & Monaghan, D. T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097394 · Cited by 81
Neuroprotective and anti‐inflammatory effects of morin in a murine model of Parkinson's disease
Lee, K. M., Lee, Y., Chun, H. J., Kim, A. H., Kim, J. Y., Lee, J. Y., Ishigami, A., & Lee, J. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23764 · Cited by 81
Liu, S., Wile, D. J., Fu, J. F., Valerio, J., Shahinfard, E., McCormick, S., Mabrouk, R., Vafai, N. M., McKenzie, J., Neilson, N., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30032-2 · Cited by 80
Farlow, M. R., Grossberg, G. T., Sadowsky, C., Meng, X., & Somogyi, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12158 · Cited by 79
Bansal, Y., Singh, R., Saroj, P., Sodhi, R. K., & Kuhad, A. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.07.010 · Cited by 79
Cerebrospinal Fluid Biomarkers for Huntington’s Disease
Byrne, L. M., & Wild, E. J. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160196 · Cited by 78
Haghmorad, D., Mahmoudi, M. B., Salehipour, Z., Jalayer, Z., Momtazi‐Borojeni, A. A., Rastin, M., Kokhaei, P., & Mahmoudi, M. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.11.009 · Cited by 78
Suarez-Lopez, J. R., Hood, N. R., Suárez-Torres, J., Gahagan, S., Gunnar, M. R., & López-Paredes, D. (2019) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2019.06.001 · Cited by 78
Antunes, M. S., Souza, L. C., Ladd, F. V. L., Ladd, A. A. B. L., Moreira, A. L., Bortolotto, V. C., Poetini, M. R., Araújo, S. M., Prigol, M., Nogueira, C. W., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01940-3 · Cited by 77
Effects of Rivastigmine on Memory and Cognition in Multiple Sclerosis
Shaygannejad, V., Janghorbani, M., Ashtari, F., Afshar, H., & Zakizade, N. (2008) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009148 · Cited by 76
Wang, D., Li, S., Zhu, X., Wang, Y., Wu, W., & Zhang, X. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1013-4 · Cited by 76
Papp, M., Gruca, P., Łasoń, M., & Willner, P. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4206-0 · Cited by 76
Naringenin promotes microglial M2 polarization and Aβ degradation enzyme expression
Yang, Z., Kuboyama, T., & Tohda, C. (2019) · Phytotherapy Research · doi:10.1002/ptr.6305 · Cited by 76
Donepezil in treatment-resistant bipolar disorder
Burt, T., Sachs, G. S., & Demopulos, C. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00320-5 · Cited by 75
Bailey, J. A., Ray, B., Greig, N. H., & Lahiri, D. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021954 · Cited by 75
Kumar, P., & Kumar, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.04.058 · Cited by 75
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
Baseman, A. S., Häger, K., Nye, J. S., Brashear, R. H., Han, J., Sano, M., Davis, B. M., & Richards, H. M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s57909 · Cited by 74
Sanson, B., Colletier, J., Xu, Y., Lang, P. T., Jiang, H., Silman, I., Sussman, J. L., & Weik, M. (2011) · Protein Science · doi:10.1002/pro.661 · Cited by 74
Sabbagh, M. N., & Cummings, J. L. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-21 · Cited by 74
Du, Y., Qu, J., Zhang, W., Bai, M., Zhou, Q., Zhang, Z., Li, Z., & Miao, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.008 · Cited by 74
Fancellu, G., Chand, K., Tomás, D., Orlandini, E., Piemontese, L., Silva, D. F., Cardoso, S. M., Chaves, S., & Santos, M. A. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1689237 · Cited by 74
Phenserine Efficacy in Alzheimer's Disease
Winblad, B. G., Giacobini, E., Frölich, L., Friedhoff, L. T., Bruinsma, G., Becker, R. E., & Greig, N. H. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101311 · Cited by 73
Yi, L., Li, J., Li, H.-C., Su, D.-X., Quan, X.-B., He, X.-C., & Wang, X. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.009 · Cited by 73
Zhang, S., Ma, J., Li, S., Zhang, D., Chen, X., Yang, J., & Wang, D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00872 · Cited by 73
Cholinergic imbalance in the multiple sclerosis hippocampus
Kooi, E., Prins, M., Bajic, N., Beliën, J. A. M., Gerritsen, W. H., van Horssen, J., Aronica, E., van Dam, A., Hoozemans, J. J. M., Francis, P. T., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0849-4 · Cited by 72
Wang, J., Qi, Y., Niu, X., Tang, H., Meydani, S. N., & Wu, D. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.12.004 · Cited by 72
Hesperidin attenuates depression-related symptoms in mice with mild traumatic brain injury
Kosari‐Nasab, M., Shokouhi, G., Ghorbanihaghjo, A., Abbasi, M. M., & Salari, A. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.040 · Cited by 72
Das, A., Kapoor, K., Sayeepriyadarshini, A. T., Dikshit, M., Palit, G., & Nath, C. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0678 · Cited by 70
Mohamed, L. A., Keller, J. N., & Kaddoumi, A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.01.013 · Cited by 70
Antunes, M. S., Jessé, C. R., Ruff, J. R., Janner, D. E., Gomes, N. S., Altvater, E. E. T., Donato, F., Giacomeli, R., & Boeira, S. P. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.07.042 · Cited by 70
Perry, N. S. L., Menzies, R., Hodgson, F., Wedgewood, P., Howes, M. R., Brooker, H. J., Wesnes, K. A., & Perry, E. K. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.08.015 · Cited by 70
Najafabad, A. M., & Jamei, R. (2014) · Europe PMC (PubMed Central) · Cited by 69
Naringenin alleviates 6-hydroxydopamine induced Parkinsonism in SHSY5Y cells and zebrafish model
Kesh, S., Kannan, R. R., & Balakrishnan, A. (2020) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2020.108893 · Cited by 69
Cummings, J. L., Geldmacher, D., Farlow, M. R., Sabbagh, M. N., Christensen, D. D., & Betz, P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12076 · Cited by 68
Morin modulates the oxidative stress-induced NF-κB pathway through its anti-oxidant activity
Kim, J. M., Lee, E. K., Park, G., Kim, M. K., Yokozawa, T., Yu, B. P., & Chung, H. Y. (2010) · Free Radical Research · doi:10.3109/10715761003610737 · Cited by 67
Reale, M., Angelis, F. D., Nicola, M. D., Capello, E., di Ioia, M., Luca, G. D., Lugaresi, A., & Tata, A. M. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012656 · Cited by 67
Matias, I. C. P., Diniz, L. P., Buosi, A. S., Neves, G. A., Stipursky, J., & Gomes, F. C. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00184 · Cited by 67
Seeing ophthalmologic problems in Parkinson disease
Borm, C. D. J. M., Visser, F., Werkmann, M., de Graaf, D., Putz, D., Seppi, K., Poewe, W. H., Vlaar, A. M. M., Hoyng, C. B., Bloem, B. R., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009214 · Cited by 67
Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat
Kiasalari, Z., Khalili, M., Baluchnejadmojarad, T., & Roghani, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1796-6 · Cited by 66
Striatal and C ortical β‐ A myloidopathy and C ognition in P arkinson's D isease
Shah, N., Frey, K. A., Müller, M. L. T. M., Petrou, M., Kotagal, V., Koeppe, R. A., Scott, P. J. H., Albin, R. L., & Bohnen, N. I. (2015) · Movement Disorders · doi:10.1002/mds.26369 · Cited by 65
Biochemical Differentiation of Cholinesterases from Normal and Alzheimers Disease Cortex
Ciro, A., Park, J., Burkhard, G., Yan, N., & Geula, C. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015127 · Cited by 65
Lee, S., Youn, K., Lim, G., Lee, J., & Jun, M. (2018) · Molecules · doi:10.3390/molecules23071509 · Cited by 65
Zhu, X., Liu, H., Liu, Y., Chen, Y., Liu, Y., & Yin, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01325 · Cited by 65
Almasieh, M., MacIntyre, J. N., Pouliot, M., Casanova, C., Vaucher, E., Kelly, M. E. M., & Polo, A. D. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11481 · Cited by 64
Donepezil for Huntington's disease
Fernandez, H. H., Friedman, J. H., Grace, J., & Beason-Hazen, S. (2000) · Movement Disorders · doi:10.1002/1531-8257(200001)15:1<173::aid-mds1032>3.0.co;2-t · Cited by 64
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease
Grace, J., Amick, M. M., & Friedman, J. H. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144048 · Cited by 64
Tel, G., Öztürk, M., Duru, M. E., Harmandar, M., & Topçu, G. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.08.020 · Cited by 63 · cited 20×
“None of the extracts had any effect on BChE in this study.”
BackgroundInfluentialHannestad, J. O., Cosgrove, K. P., DellaGioia, N. F., Perkins, E., Bois, F., Bhagwagar, Z., Seibyl, J. P., McClure-Begley, T. D., Picciotto, M. R., & Esterlis, I. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.004 · Cited by 63
Minaiyan, M., Ghannadi, A., Asadi, M., et al. (2015) · PubMed · Cited by 63
Mikkilineni, S., Cantuti‐Castelvetri, I., Cahill, C. M., Balliedier, A., Greig, N. H., & Rogers, J. T. (2012) · Parkinson s Disease · doi:10.1155/2012/142372 · Cited by 62
Inhibition effects of tanshinone on the aggregation of α-synuclein
Ji, K., Zhao, Y., Yu, T., Wang, Z., Gong, H., Yang, X., Liu, Y., & Huang, K. (2015) · Food & Function · doi:10.1039/c5fo00664c · Cited by 62
Reale, M., Costantini, E., Nicola, M. D., D’Angelo, C., Franchi, S., D’Aurora, M., Bari, M. D., Orlando, V., Galizia, S., Ruggieri, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19701-7 · Cited by 62
Kou, X., Song, L., Wang, Y., Yu, Q., Ju, H., Yang, A., & Shen, R. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126927 · Cited by 61
Bergamino, M., Keeling, E. G., Mishra, V. R., Stokes, A. M., & Walsh, R. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00314 · Cited by 61
Leporini, M., Bonesi, M., Loizzo, M. R., PASSALACQUA, N. G., & Tundis, R. (2020) · Plants · doi:10.3390/plants9060798 · Cited by 61
Biradar, S. M., Joshi, H., & Chheda, T. K. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.02.042 · Cited by 60
Parkhe, A., Parekh, P., Nalla, L. V., Sharma, N., Sharma, M., Gadepalli, A., Kate, A. S., & Khairnar, A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134652 · Cited by 60
Eckroat, T. J., Manross, D. L., & Cowan, S. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175965 · Cited by 60
Lilja, A. M., Luo, Y., Yu, Q., Röjdner, J., Li, Y., Marini, A. M., Marutle, A., Nordberg, A. K., & Greig, N. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054887 · Cited by 59
Mohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58
Sattayasai, J., Chaonapan, P., Arkaravichie, T., Soi‐ampornkul, R., Junnu, S., Charoensilp, P., Samer, J., Jantaravinid, J., Masaratana, P., Suktitipat, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085053 · Cited by 58
Gatta, V., Mengod, G., Reale, M., & Tata, A. M. (2020) · Biomedicines · doi:10.3390/biomedicines8060153 · Cited by 58
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Seltzer, B. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4819 · Cited by 57
Fedorova, T. D., Knudsen, C. S., Mouridsen, K., Nexø, E., & Borghammer, P. (2015) · Parkinson s Disease · doi:10.1155/2015/156479 · Cited by 57
Xue, N., Wu, X., Wu, L., Li, L., & Wang, F. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.11.013 · Cited by 57
Liao, D., Chen, Y., Guo, Y., Wang, C., Liu, N., Gong, Q., Fu, Y., Fu, Y., Cao, L., Yao, D., et al. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s249363 · Cited by 57
Kim, D. H., Park, S. J., Kim, J. M., Jeon, S. J., Kim, D.-H., Cho, Y., Son, K. H., Lee, H. J., Moon, J., Cheong, J. H., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.038 · Cited by 56
Tohda, C., Tamura, T., & Komatsu, K. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03449-8 · Cited by 56
Chakraborty, S., & Basu, S. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.05.110 · Cited by 56
Kuo, Y., Nwankwo, E. I., Nussbaum, R. L., Rogers, J. T., & Maccecchini, M. L. (2019) · Europe PMC (PubMed Central) · Cited by 56
Wainger, B. J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780199937837.003.0028 · Cited by 56
Vetter, J. M., Jehle, T., Heinemeyer, J., Franz, P., Behrens, P. F., Jackisch, R., Landwehrmeyer, G. B., & Feuerstein, T. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01704.x · Cited by 55
Islam, M. R., Moriguchi, S., Tagashira, H., & Fukunaga, K. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.046 · Cited by 55
Effects of rivastigmine on motor and cognitive impairment in Huntington's disease
de Tommaso, M., Specchio, N., Sciruicchio, V., Difruscolo, O., & Specchio, L. M. (2004) · Movement Disorders · doi:10.1002/mds.20235 · Cited by 55
Reale, M., Nicola, M. D., Velluto, L., D’Angelo, C., Costantini, E., Lahiri, D. K., Kamal, M. A., Yu, Q.-S., & Greig, N. H. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212113218 · Cited by 55
Jiang, S., Zhao, Y., Zhang, T., Lan, J., Yang, J., Yuan, L., Zhang, Q., Pan, K., & Zhang, K. (2018) · Cell Proliferation · doi:10.1111/cpr.12427 · Cited by 55
Antunes, M. S., Ladd, F. V. L., Ladd, A. A. B. L., Moreira, A. L., Boeira, S. P., & Souza, L. C. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00618-y · Cited by 55
Iosifescu, D. V., Moore, C. M., Deckersbach, T., Tilley, C. A., Ostacher, M. J., Sachs, G. S., & Nierenberg, A. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00090.x · Cited by 54
Huolman, S., Hämäläinen, P. I., Vorobyev, V., Ruutiainen, J., Parkkola, R. K., Laine, T., & Hämäläinen, H. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511412061 · Cited by 54
Two Years' Follow-up of Rivastigmine Treatment in Huntington Disease
de Tommaso, M., Difruscolo, O., Sciruicchio, V., Specchio, N., & Livrea, P. (2007) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000240945.44370.f0 · Cited by 54
Meng, P., Yoshida, H., Matsumiya, T., Imaizumi, T., Tanji, K., Xing, F., Hayakari, R., Dempoya, J., Tatsuta, T., Aizawa‐Yashiro, T., et al. (2012) · Neuroscience Research · doi:10.1016/j.neures.2012.11.007 · Cited by 54
α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity
Hu, Z., Wang, W., Jing, L., & Jiang, C. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0264-9 · Cited by 54
Catorce, M. N., Acero, G., Pedraza‐Chaverrí, J., Fragoso, G., Govezensky, T., & Gevorkian, G. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.05.008 · Cited by 54
Infante‐Garcia, C., Ramos‐Rodríguez, J. J., Delgado-Olmos, I., Gamero-Carrasco, C., Fernández-Ponce, M. T., Casas, L., Mantell, C., & García-Alloza, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0015-z · Cited by 54
Kowal, N. M., Ahring, P. K., Liao, V. W. Y., Indurti, D. C., Harvey, B. S., O'Connor, S. M., Chebib, M., Ólafsdóttir, E. S., & Balle, T. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14329 · Cited by 54
Gul, A., Bakht, J., & Mehmood, F. (2019) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.07.004 · Cited by 52 · cited 1×
“Patients with AD demonstrated significant improvements in cognitive function and improved ability to perform tasks [302].”
BackgroundSpring, F. A., Gardner, B., & Anstee, D. J. (1992) · Blood · doi:10.1182/blood.v80.8.2136.2136 · Cited by 51
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Holtzheimer, P. E., Meeks, T. W., Kelley, M. E., Mufti, M., Young, R., McWhorter, K., Vito, N., Chismar, R., Quinn, S., Dey, S., et al. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1951 · Cited by 50
Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients
Li, Z., Yu, Z., Zhang, J., Wang, J., Sun, C., Wang, P., & Zhang, J. (2015) · European Neurology · doi:10.1159/000438824 · Cited by 50
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
Oh, Y., Kim, J., & Lee, P. H. (2015) · Journal of Movement Disorders · doi:10.14802/jmd.15041 · Cited by 50
Liepelt, I., Gaenslen, A., Godau, J., Santo, A. D., Schweitzer, K., Gasser, T., & Berg, D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1231 · Cited by 50
Cruz, I., Puthongking, P., Cravo, S. M. M., Palmeira, A., Cidade, H. M., Pinto, M. M. M., & Sousa, E. (2017) · Journal of Chemistry · doi:10.1155/2017/8587260 · Cited by 50
Liu, C., Wu, Y., Zha, S., Liu, M., Wang, Y., Yang, G., Ma, K., Fei, Y., Zhang, Y., Hu, X., et al. (2015) · Brain Research · doi:10.1016/j.brainres.2015.11.040 · Cited by 49
Damar, U., Gersner, R., Johnstone, J. T., Schachter, S. C., & Rotenberg, A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.12.006 · Cited by 49
Acetylcholinesterase Modulates Presenilin-1 Levels and γ-Secretase Activity
Campanari, M., García‐Ayllón, M., Belbin, O., Galcerán, J., Lleó, A., & Sáez‐Valero, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140426 · Cited by 48
Chau, D. T., Rada, P. V., Kim, K., Kosloff, R. A., & Hoebel, B. G. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.54 · Cited by 48
Qin, J., Lan, W., Liu, Z., HUANG, J. C., Tang, H., & Wang, H. (2013) · Chemistry Central Journal · doi:10.1186/1752-153x-7-78 · Cited by 48
Sawada, H., Oeda, T., Kohsaka, M., Umemura, A., Tomita, S., Park, K., Mizoguchi, K., Matsuo, H., Hasegawa, K., Fujimura, H., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318107 · Cited by 48
Lecca, D., Bader, M., Tweedie, D., Hoffman, A. F., Jung, Y. J., Hsueh, S., Hoffer, B. J., Becker, R. E., Pick, C. G., Lupica, C. R., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104528 · Cited by 48
Devanand, D. P., Pelton, G. H., D'Antonio, K., Ciarleglio, A., Scodes, J., Andrews, H., Lunsford, J., Beyer, J. L., Petrella, J. R., Sneed, J., et al. (2018) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.05.008 · Cited by 47
Pozzo, L., Russo, R., Frassinetti, S., Vizzarri, F., Árvay, J., Vornoli, A., CASAMASSIMA, D., Palazzo, M., Croce, C. M. D., & Longo, V. G. (2019) · Foods · doi:10.3390/foods9010005 · Cited by 47
Baker, D. H. A., Ibrahim, B. M. M., Hassan, N. S., Yousuf, A., & Gengaihi, S. E. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.06.001 · Cited by 47
Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease
Christopher, L., & Strafella, A. P. (2013) · Journal of Neuropsychology · doi:10.1111/jnp.12015 · Cited by 46
Plasma Acetylcholinesterase Activity Correlates with Intracerebral β-Amyloid Load
Alkalay, A., Rabinovici, G. D., Zimmerman, G., Agarwal, N., Kaufer, D., Miller, B. L., Jagust, W. J., & Soreq, H. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010007 · Cited by 46
Hao, X.-M., Lian-da, L., Duan, C.-L., & Li, Y. (2017) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2017.1339349 · Cited by 46
Teich, A. F., Sharma, E., Barnwell, E., Zhang, H., Staniszewski, A., Utsuki, T., Padmaraju, V., Mazell, C., Τζέκου, Α., Sambamurti, K., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.12.001 · Cited by 46
Hesperidin downregulates kinases lrrk2 and gsk3β in a 6-OHDA induced Parkinson’s disease model
Kesh, S., Kannan, R. R., Sivaji, K., & Balakrishnan, A. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135426 · Cited by 46
Niu, X., Sang, H., & Wang, J. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108560 · Cited by 46
Bond, C. E., Patel, P., Crouch, L., Tetlow, N., Day, T., Abu‐Hayyeh, S., Williamson, C., & Greenfield, S. A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04898.x · Cited by 45
Kim, M., Bang, J. H., Lee, J. H., Han, J., Kang, H.-W., & Jeon, W. K. (2015) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3512 · Cited by 45
Akanda, M. R., Tae, H., Kim, I., Ahn, D., Tian, W., Islam, A., Nam, H., Choo, B.-K., & Park, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071482 · Cited by 45
Yun, Y. C., Jeong, S., Kim, S. H., & Cho, G. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2776 · Cited by 45
A double‐blind, placebo‐controlled trial of adjunctive donepezil in treatment‐resistant mania
Evins, A. E., Demopulos, C. M., Nierenberg, A. A., Maravić, M. C., Eisner, L. R., & Sachs, G. S. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00243.x · Cited by 44
Mazzanti, C. M. D. A., Spanevello, R. M., Ahmed, M., Pereira, L. B., Gonçalves, J. F., Corrêa, M., Schmatz, R., Stefanello, N., Leal, D. B. R., Mazzantí, A., et al. (2008) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2008.09.005 · Cited by 44
Guedes, L., Reis, P. B. P. S., Machuqueiro, M., Ressaissi, A., Pacheco, R., & Serralheiro, M. L. (2019) · Molecules · doi:10.3390/molecules24203795 · Cited by 44
Zhao, J., Liu, X., Chang, D., Zhang, X., Lian, H., Du, X., & Gao, L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00669 · Cited by 44
Bioactive constituents of Salvia chrysophylla Stapf
Çulhaoğlu, B., Yapar, G., Di̇rmenci̇, T., & Topçu, G. (2012) · Natural Product Research · doi:10.1080/14786419.2012.734820 · Cited by 43
Viswanatha, G. L., Shylaja, H., Rao, K. S. S., Kumar, V. R. S., & Jagadeesh, M. (2012) · ISRN Pharmacology · doi:10.5402/2012/479570 · Cited by 43
Sethiya, N. K., & Mishra, S. H. (2014) · Journal of Biologically Active Products from Nature · doi:10.1080/22311866.2014.921121 · Cited by 43
Blotnick-Rubin, E., & Anglister, L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00123 · Cited by 43
Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease
Possin, K. L., Kang, G. A., Guo, C. C., Fine, E. M., Trujillo, A. J., Racine, C. A., Wilheim, R., Johnson, E. T., Witt, J. L., Seeley, W. W., et al. (2013) · Movement Disorders · doi:10.1002/mds.25575 · Cited by 42
Tulino, R., Benjamin, A. C., Jolinon, N., Smith, D. L., Chini, E. N., Carnemolla, A., & Bates, G. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145425 · Cited by 42
Tweedie, D., Fukui, K., Li, Y., Yu, Q.-S., Barak, S., Tamargo, I. A., Rubovitch, V., Holloway, H. W., Lehrmann, E., Wood, W. H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156493 · Cited by 42
Coppari, S., Colomba, M., Fraternale, D., Brinkmann, V., Romeo, M., Rocchi, M., Giacomo, B. D., Mari, M., Guidi, L., Ramakrishna, S., et al. (2021) · Antioxidants · doi:10.3390/antiox10030374 · Cited by 42
Farrar, A. M., Callahan, J. W., & Abercrombie, E. D. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.08.010 · Cited by 41
Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients
Bari, M. D., Reale, M., Nicola, M. D., Orlando, V., Galizia, S., Porfilio, I., Costantini, E., D’Angelo, C., Ruggieri, S., Biagioni, S., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122009 · Cited by 41
Design of potent inhibitors of acetylcholinesterase using morin as the starting compound
Remya, C., Dileep, K. V., Tintu, I., Variyar, E. J., & Sadasivan, C. (2012) · Frontiers in Life Science · doi:10.1080/21553769.2013.815137 · Cited by 40
Rada, P. V., Colasante, C., Skirzewski, M., Hernandez, L., & Hoebel, B. G. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.03.043 · Cited by 40
Kish, S. J., Schut, L. J., Simmons, J., Gilbert, J., Chang, L. J., & Rebbetoy, M. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.4.544 · Cited by 40
Xie, J., Jiang, H. L., Wan, Y., Du, A., Guo, K., Liu, T., Ye, W., Niu, X., Wu, J., Dong, X., et al. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq047 · Cited by 40
Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease
Emre, M., Bernabei, R., Blesa, R., Bullock, R. A., Cunha, L., Daniëls, H., Dziadulewicz, E. K., Förstl, H., Frölich, L., Gabryelewicz, T., et al. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00141.x · Cited by 39
Morphoregulation by acetylcholinesterase in fibroblasts and astrocytes
Anderson, A. A., Ushakov, D. S., Ferenczi, M. A., Mori, R., Martin, P. B., & Saffell, J. L. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21288 · Cited by 39
Manivasagam, T., Nataraj, J., Tamilselvam, K., Essa, M., & Janakiraman, U. (2013) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/2231-0738.114875 · Cited by 39
Cutillas, A., Carrasco, A., Martinez‐Gutierrez, R., Pérez‐Ruiz, T., & Tudela, J. (2018) · Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology · doi:10.1080/11263504.2018.1445129 · Cited by 39
Antidepressant-Like Effects of Hesperidin in Animal Model of Post-Traumatic Stress Disorder
Lee, B., Choi, G., & Sur, B. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-2724-4 · Cited by 39
LEI, L.-Y., WANG, R.-C., PAN, Y.-L., YUE, Z.-G., ZHOU, R., XIE, P., & TANG, Z.-S. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60012-2 · Cited by 39
Huang, H.-J., Chen, W.-L., Hsieh, R., & Hsieh‐Li, H. M. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/813672 · Cited by 38
Li, B., Huang, A.-L., Zhang, Y., Li, Z., Ding, H.-W., Huang, C., Meng, X., & Li, J. (2017) · Molecules · doi:10.3390/molecules22071067 · Cited by 38
(−)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury
Chang, C.-F., Lai, J.-H., Wu, J. C.-C., Greig, N. H., Becker, R. E., Luo, Y., Chen, Y., Kang, S.-J., Chiang, Y. H., & Chen, K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.015 · Cited by 38
Fitzgerald, P. J., Hale, P. J., Ghimire, A., & Watson, B. O. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00928-w · Cited by 38
The effects of an orally administered cholinergic agonist on REM sleep in major depression
Perlis, M. L., Smith, M. T., Orff, H. J., Andrews, P. J., Gillin, J. C., & Giles, D. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01287-2 · Cited by 37
Altınyazar, V., ŞİRİN, F. B., Sütçü, R., Eren, İ., & Ömürlü, İ. K. (2016) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-016-0558-9 · Cited by 37
Tau phosphorylation by glycogen synthase kinase 3β modulates enzyme acetylcholinesterase expression
Cortés‐Gómez, M., Llorens‐Álvarez, E., Alom, J., del Ser, T., Ávila, J., Sáez‐Valero, J., & García‐Ayllón, M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15189 · Cited by 37
Acetylcholinesterase‐R increases germ cell apoptosis but enhances sperm motility
Mor, I., Sklan, E. H., Podoly, E., Pick, M., Kirschner, M., Yogev, L., Itach, S. B., Schreiber, L., Geyer, B. C., Mor, T. S., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00231.x · Cited by 36
Du, Y., Liang, H., Zhang, L., & Fu, F. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.06.002 · Cited by 36
Overlap between age-at-onset and disease-progression determinants in Huntington disease
Aziz, N. A., van der Burg, J. M. M., Tabrizi, S. J., & Landwehrmeyer, G. B. (2018) · Neurology · doi:10.1212/wnl.0000000000005690 · Cited by 36
Dalès, J.-P., & Desplat‐Jégo, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239105 · Cited by 36
Ramakrishnan, N., Visser, A. K. D., Schepers, M., Luurtsema, G., Nyakas, C., Elsinga, P., Ishiwata, K., Dierckx, R., & van Waarde, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3533-2 · Cited by 35
Gildengers, A. G., Butters, M. A., Chisholm, D., Reynolds, C. F., & Mulsant, B. H. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1962 · Cited by 35
Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease.
Schegg, K., Harrington, L., Neilsen, S., Zweig, R., & Peacock, J. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90092-c · Cited by 35
Ghaemi, S. N., Gilmer, W. S., Dunn, R. T., Hanlon, R. E., Kemp, D. E., Bauer, A., Chriki, L. S., Filkowski, M. M., & Harvey, P. D. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a497d7 · Cited by 35
Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice
Silveyra, M. X., García‐Ayllón, M., de Barreda, E. G., Small, D. H., Martínez, S., Ávila, J., & Sáez‐Valero, J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.006 · Cited by 35
Luo, L., Li, Y., Qiang, X., Cao, Z., Xu, R., Xia, Y., Xiao, G., Song, Q., Tan, Z., & Deng, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.027 · Cited by 35
Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine
Hoffer, B. J., Pick, C. G., Hoffer, M. E., Becker, R. E., Chiang, Y. H., & Greig, N. H. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0377-1 · Cited by 35
Early Reactive A1 Astrocytes Induction by the Neurotoxin 3-Nitropropionic Acid in Rat Brain
López‐Sánchez, C., García‐Martínez, V., Poejo, J., García‐López, V., Salazar, J., & Gutiérrez‐Merino, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103609 · Cited by 35
Oh, Y., Do, H. T. T., Kim, S.-Y., Kim, Y., Chin, Y., & Cho, J. (2020) · Antioxidants · doi:10.3390/antiox10010034 · Cited by 35
Effects of Donepezil on Compulsive Hypersexual Behavior in Parkinson Disease
Ivanco, L. S., & Bohnen, N. I. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000151861.59698.26 · Cited by 34
Fructus mume extracts alleviate cognitive impairments in 5XFAD transgenic mice
Park, J.-C., Ma, J., Jeon, W. K., & Han, J. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1033-0 · Cited by 34
Cheng, J., Yang, H., & Zhang, J. (2019) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000324 · Cited by 34
AMPK Ameliorates Tau Acetylation and Memory Impairment Through Sirt1
Wang, L., Shi, F.-X., Li, N., Cao, Y., Lei, Y., Wang, J., Tian, Q., & Zhou, X. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02079-x · Cited by 34
Donepezil for mild cognitive impairment in Parkinson’s disease
Baik, K., Kim, S. M., Jung, J. H., Lee, Y. H., Chung, S. J., Yoo, H. S., Ye, B. S., Lee, P. H., Sohn, Y. H., Kang, S. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84243-4 · Cited by 34
The pharmacology and therapeutic potential of (-)-huperzine A
Herzon, S. B., & Tun, M. K. M. (2012) · Journal of Experimental Pharmacology · doi:10.2147/jep.s27084 · Cited by 33
Liu, S., Chan, P., & Stoessl, A. J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0074-8 · Cited by 33
Huang, Y., Sun, L., Zhu, S., Liu, X., Liu, S., Yuan, C., Guo, Y., & Xuemin, W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00723 · Cited by 33
Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension
Espay, A. J., Marsili, L., Mahajan, A., Sturchio, A., Pathan, R. B., Pilotto, A., Elango, D. S., Pezous, N., Masellis, M., & Gomez‐Mancilla, B. (2020) · Annals of Neurology · doi:10.1002/ana.25923 · Cited by 33
Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia
Schmitt, F. A., Farlow, M. R., Meng, X., Tekin, S., & Olin, J. T. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00182.x · Cited by 32
Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels
Silveyra, M. X., García‐Ayllón, M., Serra‐Basante, C., Mazzoni, V., García‐Gutiérrez, M. S., Manzanares, J., Culvenor, J. G., & Sáez‐Valero, J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.006 · Cited by 32
Xiao, T., Jiao, B., Zhang, W., Tang, B., & Shen, L. H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0356-1 · Cited by 32
α‐Mangostin decreases β‐amyloid peptides production via modulation of amyloidogenic pathway
Zhao, L., Wang, Y., Liu, T., Wang, Y., Chen, H., Xu, J., & Qiu, Y. L. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12699 · Cited by 32
TDP-43 Regulation of AChE Expression Can Mediate ALS-Like Phenotype in Zebrafish
Campanari, M., Marian, A., Ciura, S., & Kabashi, E. (2021) · Cells · doi:10.3390/cells10020221 · Cited by 32
Megala, M., Shivaramakrishnan, B., Manikandan Kishore, R., & Balashanmugam, K. (2021) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.110203 · Cited by 32
Salman, M., Sharma, P., Alam, I., Tabassum, H., & Parvez, S. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.1913319 · Cited by 32
Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease
Jean, L., Thomas, B., Tahiri‐Alaoui, A., Shaw, M. K., & Vaux, D. J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000652 · Cited by 31
Mäurer, M., Ortler, S., Baier, M. L., Meergans, M., Scherer, P., Hofmann, W., & Tracik, F. M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512463481 · Cited by 31
Şenol, F. S., Orhan, İ. E., Erdem, S. A., Kartal, M., Şener, B., Kan, Y., Celep, F., Kahraman, A., & Doğan, M. (2011) · Journal of Medicinal Food · doi:10.1089/jmf.2010.0158 · Cited by 31
Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer’s Disease
Rampa, A., Bartolini, M., Pruccoli, L., Naldi, M., Iriepa, I., Moraleda, I., Belluti, F., Gobbi, S., Tarozzi, A., & Bisi, A. (2018) · Molecules · doi:10.3390/molecules23081902 · Cited by 31
Rajeshwari, R., Chand, K., Candeias, E., Cardoso, S. M., Chaves, S., & Santos, M. A. (2019) · Molecules · doi:10.3390/molecules24030587 · Cited by 31
Zhou, Z., Müller, M. L. T. M., Kanel, P., Chua, J., Kotagal, V., Kaufer, D., Albin, R. L., Frey, K. A., & Bohnen, N. I. (2019) · Neurology · doi:10.1212/wnl.0000000000008683 · Cited by 31
Guan, H., Li, J., Tan, X., Luo, S., Liu, Y., Meng, Y., Wu, B., Zhou, Y., Yang, Y., Chen, H., et al. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000096 · Cited by 31
Tariot, P. N., Salloway, S., Yardley, J., Mackell, J. A., & Moline, M. L. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-283 · Cited by 30
Baradaran, S., Moghaddam, A. H., & Ghasemi‐Kasman, M. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.001 · Cited by 30
Bonesi, M., Tenuta, M. C., Loizzo, M. R., Sicari, V., & Tundis, R. (2018) · Antioxidants · doi:10.3390/antiox8010002 · Cited by 30
Geng, L., Liu, W., & Chen, Y. (2019) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-019-0102-1 · Cited by 30
Cited by
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
“140 These enzymes are critically involved in inflammation regulation, phagocytosis, autophagy, and pathological protein degradation, making them ideal “pathological microenvironmental triggers” for designing enzyme-responsive delivery systems.”
Metal Nanoparticles in Alzheimer’s Disease
Behera, A., Sa, N., Pradhan, S. P., Swain, S., & Sahu, P. K. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220112 · Cited by 50
Metadata
- Authors
- Walczak-Nowicka, Ł. J., & Herbet, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-27
- Volume
- 22
- Issue
- 17
- Pages
- 9290
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3197674566
- Cited by
- 335
- References
- 512
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.